MDM2 and cancer: In malignant tumors, a study using second-generation sequencing found that the amplification rate of MDM2/4 was about 3.9% (6/155), and that the TTF of all patients with MDM2/4 amplification receiving immunotherapy was less than 2 months (Champiat et al., 2018).